Coronary CT Angio Evaluating Graft Patency in ACS Patients Treated With DAPT or Single ASA After CABG (CoCAP)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04783701

Enrollment

360

Registered

2021-03-05

Start date

2021-05-17

Completion date

2026-03-15

Last updated

2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Coronary Bypass Stenosis

Keywords

Acute coronary syndrome, Coronary bypass surgery, Coronary computed tomography angiography, Antiplatelet therapy

Brief summary

The purpose of this study is to compare the presence of graft patency in single aspirin vs dual anti platelet therapy (DAPT) treatment including ticagrelor in patients with acute coronary syndrome (ACS) treated with coronary artery bypass surgery (CABG). Follow up time is 12-36 months postoperatively and the patency will be evaluated with coronary computed tomography angiography (CCTA)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Previously included in TACSI-trial

Exclusion criteria

* Highly irregular heart rhythm (i.e. atrial fibrillation) * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<45ml/min/1,73m2 * Body weight \>120 kg * Previous severe allergic reaction (i.e. anaphylactic reaction) to iodine-based contrast agents * Not able to communicate * Not willing to participate

Design outcomes

Primary

Measure	Time frame	Description
Graft patency after CABG	12-36 months	Defined as patency on CCTA (FitzGibbon A) without previous graft failure identified on CCTA and/or invasive coronary angio (ICA) since CABG, intention to treat (ITT) analysis.

Secondary

Measure	Time frame	Description
Graft patency after CABG - PP analysis	12-36 months	Defined as patency on CCTA (FitzGibbon A) without previous graft failure identified on CCTA and/or ICA since CABG, per protocol (PP) analysis.
Graft patency after CABG	12-36 months	Defined as non-occlusion on CCTA (FitzGibbon A+B) without previous graft occlusion identified on CCTA and/or ICA since CABG, ITT analysis.

Other

Measure	Time frame	Description
Subgroup analyses	12-36 months	Possible interactions in response to study treatment, with special focus on the following factors; age, gender, renal function, diabetes, oral anticoagulant therapy, adherence to study treatment and time from end of study medication.
Explorative analyses	12-36 months	Performed on the graft patency of internal mammary artery (IMA) in the two treatment groups, as well as if there are any differences in graft patency between different anastomoses and grafting techniques. Possible predictors of graft failure in general, with age, gender, diabetes, obesity, renal failure, urgency level and length of surgery, per-operative complications, number and type of graft as well as pre-operative fractional flow reserve as variables to explore. Gender analysis will be performed, analyzing if female gender is associated with worse prognosis post CABG, adjusting for their higher age and burden of co-morbidities.

Countries

Norway, Sweden

Contacts

Primary ContactJonas Holm, MD, PhD

jonas.holm@regionostergotland.se+46101034498

Backup ContactSofia Sederholm Lawesson, MD, PhD

sofia.sederholm.lawesson@regionostergotland.se+461037472

Outcome results